Bristol-Myers Squibb Co banner

Bristol-Myers Squibb Co
XHAM:BRM

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
XHAM:BRM
Watchlist
Price: 52.58 EUR 2.2% Market Closed
Market Cap: €116.7B

Relative Value

The Relative Value of one BRM stock under the Base Case scenario is hidden EUR. Compared to the current market price of 52.58 EUR, Bristol-Myers Squibb Co is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BRM Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

BRM Competitors Multiples
Bristol-Myers Squibb Co Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Bristol-Myers Squibb Co
XHAM:BRM
125.7B EUR 2.6 17.8 7.4 9.2
US
Eli Lilly and Co
NYSE:LLY
963B USD 14.8 46.7 31.4 33.6
US
Johnson & Johnson
NYSE:JNJ
599.3B USD 6.4 22.4 15.5 19.1
CH
Roche Holding AG
SIX:ROG
288.1B CHF 4.7 30.6 12.9 15.1
CH
Novartis AG
SIX:NOVN
250B CHF 5.7 23 14.2 18.2
UK
AstraZeneca PLC
LSE:AZN
237.1B GBP 5.4 31.2 17.3 24.4
US
Merck & Co Inc
NYSE:MRK
300.9B USD 4.6 16.5 10.2 12.4
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
DK
Novo Nordisk A/S
CSE:NOVO B
1T DKK 3.4 10.3 7.6 8.9
US
Pfizer Inc
NYSE:PFE
155.1B USD 2.5 20 7.7 10.2
UK
GSK plc
XETRA:GS71
102.1B EUR 2.7 15.6 7.9 11.2
P/E Multiple
Earnings Growth PEG
US
Bristol-Myers Squibb Co
XHAM:BRM
Average P/E: 23.4
17.8
17%
1
US
Eli Lilly and Co
NYSE:LLY
46.7
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
22.4
7%
3.2
CH
Roche Holding AG
SIX:ROG
30.6
29%
1.1
CH
Novartis AG
SIX:NOVN
23
15%
1.5
UK
AstraZeneca PLC
LSE:AZN
31.2
26%
1.2
US
Merck & Co Inc
NYSE:MRK
16.5
14%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
7%
1.5
US
Pfizer Inc
NYSE:PFE
20
26%
0.8
UK
GSK plc
XETRA:GS71
15.6
18%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Bristol-Myers Squibb Co
XHAM:BRM
Average EV/EBITDA: 43.4
7.4
-10%
N/A
US
Eli Lilly and Co
NYSE:LLY
31.4
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
15.5
2%
7.8
CH
Roche Holding AG
SIX:ROG
12.9
5%
2.6
CH
Novartis AG
SIX:NOVN
14.2
5%
2.8
UK
AstraZeneca PLC
LSE:AZN
17.3
13%
1.3
US
Merck & Co Inc
NYSE:MRK
10.2
3%
3.4
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.6
2%
3.8
US
Pfizer Inc
NYSE:PFE
7.7
-9%
N/A
UK
GSK plc
XETRA:GS71
7.9
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Bristol-Myers Squibb Co
XHAM:BRM
Average EV/EBIT: 93.4
9.2
-7%
N/A
US
Eli Lilly and Co
NYSE:LLY
33.6
22%
1.5
US
Johnson & Johnson
NYSE:JNJ
19.1
7%
2.7
CH
Roche Holding AG
SIX:ROG
15.1
6%
2.5
CH
Novartis AG
SIX:NOVN
18.2
9%
2
UK
AstraZeneca PLC
LSE:AZN
24.4
21%
1.2
US
Merck & Co Inc
NYSE:MRK
12.4
6%
2.1
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.9
3%
3
US
Pfizer Inc
NYSE:PFE
10.2
-4%
N/A
UK
GSK plc
XETRA:GS71
11.2
7%
1.6
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett